http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-052887-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b8726f713a6d86892687edccfa03d886 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 |
| filingDate | 2006-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-052887-A1 |
| titleOfInvention | DERIVATIVES OF TIAZOL, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT DISEASES MEDIATED BY THE INHIBITION OF PROTEIN KINASE |
| abstract | Pharmaceutical compositions comprising said compounds and methods for using said compounds to treat or prevent diseases or disorders associated with the abnormal or deregulated activity of the kinase, particularly diseases or disorders comprising the abnormal activation of the kinase Ab1, Bcr-Ab1, FGFR3 , PDGFRbeta and b-Raf. Claim 1: A compound of formula (1), wherein: n is selected from 0, 1, 2, 3 and 4; Y is selected from C, S, S (O) P and P (O); R1 is selected from C1-6 alkyl, C6-10 aryl-C0-4 alkyl, C5-10 heteroarylC0-4 alkyl, C3-12 cycloalkyl-C0-4 alkyl, heterocycloC3-8 alkyl- C0-4 alkyl and -XNR7R8; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R 1 is substituted with 1-3 radicals independently selected from halo, C 1-6 alkyl, C 1-6 alkyl substituted by halo, C 1-6 alkoxy, C 1-6 alkoxy substituted by halo, C1-6 alkylthio, C1-6 alkylthio substituted with halo, -XNR7R8, -XNR7XNR7R8, -XNR7R9, C6-10 aryl, C5-10 heteroaryl, C3-12 cycloalkyl and C3-8 heterocycloalkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent on R1 may be optionally substituted with 1 to 3 radicals independently selected from halo, C1-6 alkyl, C1-6 alkyl substituted with halo, C1-6 alkyl substituted with hydroxy, C1 alkoxy -6 and C1-6 alkoxy substituted with halo; and wherein any alkyl of R1 can have a methylene replaced with O; wherein X is independently selected from a bond and C1-6 alkylene; R7 and R8 independently select hydrogen and C1-6 alkyl; wherein any methylene of R7 and R8 can be replaced with O; wherein R9 is selected from C6-10 arylC0-4 alkyl, C5-10 heteroarylC0-4 alkyl, C3-12 cycloalkylC0-4 alkyl, and C3-8 heterocycloalkylC0-4 alkyl; R2 is selected from hydrogen and C1-6 alkyl; R3 is selected from hydrogen and C1-6 alkyl; R4 is selected from halo, C1-6 alkyl, halo substituted C1-6 alkyl, C1-6 alkoxy, halo substituted C1-6 alkoxy, C1-6 alkylthio and C1-6 alkylthio with halo; R5 is selected from hydrogen and C1-6 alkyl; and R6 is selected from C6-10 aryl, C5-10 heteroaryl, C3-12 cycloalkyl and C3-8 heterocycloalkyl; wherein said aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R6 is optionally substituted with 1 to 3 substituents independently selected from halo, C1-6 alkyl, C1-6 alkyl substituted with halo, C1-6 alkoxy, C1-6 alkoxy substituted with halo, C1-6 alkylthio, C1-6 alkylthio substituted with halo, C6-10 aryl, C5-10 heteroaryl, C3-12 cycloalkyl, and C3-8 heterocycloalkyl; wherein the aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituents at R6 may optionally be substituted with 1 to 3 radicals independently selected from hydroxy, halo, C1-6 alkyl, halo substituted C1-6 alkyl, hydroxy substituted C1-6 alkyl, C1-6 alkoxy and C1-6 alkoxy substituted with halo; and pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs of said compounds. |
| priorityDate | 2005-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.